CD274 and neoplasm: All ten studies used monoclonal antibodies to target the PD-1/PD-L1 axis in at least one subpopulation of their cohort, with three also administering this concurrently with radiotherapy [34], αCTLA-4 [35], or whole tumour-cell vaccines [36].